Fig. 4

HCC cell-derived exosomes induced sorafenib resistance in SMMC-7721 cells. a IC₅₀ values of sorafenib in SMMC-7721, MHCC-97 L and MHCC-97H cells determined by MTT assay (* P <0.05). The cells were treated with sorafenib for 48 h, and the sensitivity of SMMC-7721 cells to sorafenib was higher than that of MHCC-97 L and MHCC-97H cells (* P <0.05). b Cell viability was assessed by MTT assays. HCC cell-derived exosomes attenuated sorafenib-induced cell suppression. SMMC-7721 cells were treated with sorafenib at different concentrations with or without exosomes for 48 h (* P <0.05). c IC₅₀ values for sorafenib in SMMC-7721 cells with or without exosomes determined by MTT assays. The SMMC-7721 cells were treated with sorafenib at different concentrations with or without exosomes for 48 h. The IC₅₀ of sorafenib in SMMC-7721 cells in the HCC-derived exosome groups was notably elevated compared to that of the sorafenib alone group (* P <0.05; ** P <0.01). d MHCC-97H derived exosomes prevented the reduction of SMMC-7721 viability induced by sorafenib in a time- and dose-dependent manner (* P <0.05). Cell viability was assessed by MTT assays. The SMMC-7721 cells were treated with sorafenib at 10 μM with or without exosomes at different concentrations for 24 or 48 h